Addimmune, Clinical Stage HIV-Focused Gene Therapy Company, To Go Public Through Business Combination With SPAC 10x Capital Venture Acquisition Corp. III
Portfolio Pulse from Benzinga Newsdesk
Clinical stage gene therapy company, Addimmune, is set to go public through a business combination with SPAC 10x Capital Venture Acquisition Corp. III (VCXB).
August 10, 2023 | 5:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
10x Capital Venture Acquisition Corp. III (VCXB) is merging with Addimmune, a clinical stage gene therapy company. This could potentially increase the value of VCXB shares.
The merger with Addimmune, a company in the promising field of gene therapy, could potentially increase the value of VCXB shares. However, the actual impact will depend on the terms of the deal and the market's perception of Addimmune's potential.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100